Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
NOVATO, Calif., May 01, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 7, 2018 at 5pm ET to discuss first quarter 2018 financial results and provide a corporate update.
The live and replayed webcast of the call will be available through the company’s website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 3748439. The replay of the call will be available for one year.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
